PSP in Non-Western Populations

PSP in Non-Western Populations

Overview

Progressive supranuclear palsy (PSP) has historically been studied primarily in Western populations, but increasing research from non-Western countries has revealed important variations in epidemiology, genetics, clinical presentation, and healthcare access. This page synthesizes evidence from Asian, African, Latin American, and other non-Western populations, highlighting both shared features and population-specific findings that inform our understanding of PSP globally[@psp2023].

Epidemiology in Asian Populations

Japan

Japan has conducted some of the most comprehensive epidemiological studies on PSP in Asia. Population-based studies from Japan report a prevalence of 4-6 per 100,000, somewhat lower than Western estimates of 5-7 per 100,000.

Key Japanese studies have revealed:

• Age of onset tends to be slightly later than in Western populations (mean 67-70 years)
• Clinical phenotype distribution differs, with higher proportions of PSP-Parkinsonism variant
• Autopsy-confirmed cases suggest underdiagnosis, particularly of atypical variants

Recent Japanese research has also focused on the H1 haplotype frequency in the Japanese population, finding similar associations with PSP risk but with different sub-haplotype patterns compared to European populations[@mapt2022].

China

Chinese epidemiological studies have provided crucial data on PSP in East Asia. Hospital-based studies suggest a prevalence of 2-5 per 100,000, though community-based studies are limited[@chinese2023].

...

PSP in Non-Western Populations

Overview

Progressive supranuclear palsy (PSP) has historically been studied primarily in Western populations, but increasing research from non-Western countries has revealed important variations in epidemiology, genetics, clinical presentation, and healthcare access. This page synthesizes evidence from Asian, African, Latin American, and other non-Western populations, highlighting both shared features and population-specific findings that inform our understanding of PSP globally[@psp2023].

Epidemiology in Asian Populations

Japan

Japan has conducted some of the most comprehensive epidemiological studies on PSP in Asia. Population-based studies from Japan report a prevalence of 4-6 per 100,000, somewhat lower than Western estimates of 5-7 per 100,000.

Key Japanese studies have revealed:

• Age of onset tends to be slightly later than in Western populations (mean 67-70 years)
• Clinical phenotype distribution differs, with higher proportions of PSP-Parkinsonism variant
• Autopsy-confirmed cases suggest underdiagnosis, particularly of atypical variants

Recent Japanese research has also focused on the H1 haplotype frequency in the Japanese population, finding similar associations with PSP risk but with different sub-haplotype patterns compared to European populations[@mapt2022].

China

Chinese epidemiological studies have provided crucial data on PSP in East Asia. Hospital-based studies suggest a prevalence of 2-5 per 100,000, though community-based studies are limited[@chinese2023].

Notable findings from Chinese research:

• Lower reported prevalence may reflect both genetic factors and diagnostic practices
• Clinical presentation tends to include more prominent gait disturbance early in the disease
• PSP-Cerebellar variant may be more common than in Western populations
• Limited access to specialized movement disorder centers affects detection rates

The Chinese population has shown unique MAPT haplotype patterns, with the H1c subhaplotype showing stronger association with PSP than in European populations[@mapt2022].

South Korea

Korean studies have documented PSP epidemiology with findings similar to other East Asian populations. A national health insurance database analysis revealed increasing diagnosis rates over time, suggesting improved recognition[@korea2023].

Key Korean findings:

• Prevalence estimated at 3-4 per 100,000
• Slight male predominance (1.3:1 ratio)
• Age of onset around 65-68 years
• Most common phenotype remains Richardson's syndrome

India

India represents a significant population with limited but growing PSP research. Hospital-based studies from major neurology centers in India have documented clinical characteristics[@india2021].

Indian epidemiological considerations:

• True prevalence difficult to determine due to limited diagnostic infrastructure
• Studies suggest underdiagnosis, particularly in rural areas
• Clinical presentation similar to Western populations
• Young-onset PSP (under 50 years) may be slightly more common

Genetic studies in Indian populations have identified shared MAPT risk alleles with European populations, but also novel variants that require further investigation.

Sub-Saharan Africa

Research on PSP in Sub-Saharan Africa remains extremely limited, representing a significant gap in global understanding[@psp2022].

Available evidence suggests:

• Very few documented cases, likely reflecting both true rarity and underdiagnosis
• Limited access to movement disorder specialists affects recognition
• No population-based prevalence studies have been conducted
• Genetic studies essentially absent

The lack of data from Sub-Saharan Africa represents a critical gap in understanding PSP globally. Factors contributing to this gap include:

• Limited neurology workforce and diagnostic facilities
• Competing health priorities with more prevalent conditions
• Lack of awareness among healthcare providers
• Post-mortem studies rarely performed

Latin America

Latin American countries have contributed increasingly to PSP research, with studies from Brazil, Argentina, and other countries.

Brazil

Brazilian studies represent the most extensive Latin American research on PSP. Studies from the Federal University of São Paulo and other centers have documented clinical characteristics[@brazil2022].

Brazilian findings:

• Prevalence estimates of 4-6 per 100,000 in urban areas
• Clinical presentation generally similar to Western populations
• Common variants include Richardson's syndrome and PSP-P
• Access to healthcare varies significantly by region

Argentina

Argentine research has contributed to understanding PSP in South America. Studies from Buenos Aires have documented clinical and demographic characteristics[@argentina2021].

Notable findings:

• Similar age of onset (64-67 years) to other populations
• Male predominance (1.4:1 ratio)
• Richardson's syndrome most common phenotype
• Limited access to advanced diagnostic technologies in public healthcare

Regional Considerations

Latin American research highlights important healthcare disparities:

• Significant urban-rural divide in diagnosis and management
• Limited access to specialized movement disorder care
• Financial barriers to advanced diagnostics and treatments
• Cultural factors affecting disease recognition and help-seeking

Genetic Variations Across Populations

MAPT Haplotype Diversity

The MAPT H1 haplotype is the strongest genetic risk factor for PSP, but its structure varies across populations[@mapt2022].

Population-specific findings:

• European: H1c subhaplotype most strongly associated
• East Asian: Different subhaplotype pattern (H1b and H1d more relevant)
• African: H1 frequency lower, different haplotype structure
• South Asian: Intermediate pattern between European and East Asian

Rare Genetic Variants

Population-specific rare variants have been identified:

• Novel MAPT mutations reported in Asian families
• Potential protective variants in some African populations
• Founder mutations identified in isolated populations

Clinical Presentation Variations

While core clinical features are consistent across populations, some variations have been noted:

| Feature | Western | East Asian | South Asian | Latin America |
|---------|---------|------------|-------------|---------------|
| Mean age of onset | 63-65 years | 66-70 years | 62-67 years | 64-67 years |
| Male ratio | 1.3-1.5:1 | 1.2-1.4:1 | 1.3:1 | 1.4:1 |
| PSP-RS frequency | 50-60% | 40-50% | 45-55% | 50-55% |
| PSP-P frequency | 25-30% | 30-35% | 25-30% | 25-30% |
| Early falls | 70% | 65% | 70% | 65% |

Healthcare Disparities

Diagnostic Access

Non-Western populations face significant diagnostic challenges:

• Limited access to movement disorder specialists
• Lack of advanced neuroimaging in many settings
• Limited availability of PET/SPECT imaging for differential diagnosis
• Few specialists trained in detailed neurological examination

Treatment Access

Therapeutic access disparities are substantial:

• Limited availability of standard treatments (amantadine, botulinum toxin)
• Minimal access to experimental therapies and clinical trials
• Geographic barriers to specialized rehabilitation services
• Financial constraints affecting medication adherence

Research Participation

Clinical trial participation shows marked disparities:

• Less than 5% of PSP clinical trial participants from non-Western populations
• Genetic studies predominantly European ancestry
• Biomarker validation rarely includes non-Western samples
• Need for inclusive research designs

Future Directions

Research Priorities

Epidemiological studies: Population-based studies in understudied regions

Genetic characterization: Whole-genome studies in diverse populations

Clinical phenotype documentation: Standardized assessments across populations

Healthcare access research: Understanding barriers to care

Infrastructure Development

• Training of neurologists in movement disorders across regions
• Development of telemedicine for remote consultation
• Establishment of regional reference centers
• Creation of population-specific diagnostic guidelines

International Collaboration

Global research initiatives should prioritize:

• Data sharing across geographic regions
• Standardized assessment protocols
• Capacity building in low-resource settings
• Inclusion of diverse populations in clinical trials

Cross-References

• [PSP Epidemiology](/diseases/psp-epidemiology) — general epidemiology
• [PSP Genetics](/diseases/psp-genetics) — genetic factors
• [PSP Clinical Variants](/diseases/psp-clinical-variants) — phenotype variations
• [CurePSP Foundation](/organizations/curepsp) — patient organization

References

Unknown, PSP epidemiology in Asian populations (2023)

Unknown, MAPT genetic variation in Asian PSP patients (2022)

Unknown, Chinese PSP epidemiology (2023)

Unknown, PSP in African populations (2022)

Unknown, Korean PSP epidemiology (2023)

Unknown, Indian PSP clinical characteristics (2021)

Unknown, Brazilian PSP epidemiology (2022)

Unknown, Argentine PSP clinical features (2021)